Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03272919 · ClinicalTrials.gov registry record · NA
Chemotherapy Induced Peripheral Neuropathy (CIPN)
A NA study, sponsored by Loma Linda University.
- Completed
- Registry status
- NA
- Development phase
- 44
- Enrollment target
NCT03272919 is a NA study that has completed, run by Loma Linda University. The registered enrollment target is 44 participants.
The verdict
NCT03272919, a NA study, has completed, sponsored by Loma Linda University.
- COMPLETED
- Registry status
- NA
- Development phase
- 44 participants
- Enrollment target
Study Summary
Chemotherapy induced peripheral neuropathy (CIPN) is a common side effect of many forms of chemotherapy having a negative impact on the quality of life for cancer survivors due to numbness, decreased sensation, pain (of various intensities in the extremities), gait/balance problems, and difficulty with fine motor skills of the hands and fingers.To date, there are no preventive modalities to mitigate CIPN development.When CIPN becomes intolerable, optimal doses of chemotherapy have to be reduced or discontinued, which may affect a patient's overall survival. Intraneural facilitation (INF) is a technique developed by physical therapists at Loma Linda University after careful study of the structure, pathophysiology and biomechanics of peripheral nerves. The focus of INF is restoration of circulation to an ischemic nerve. INF has been offered to subjects receiving treatment at LLUCC with anecdotal success. The purpose of this study is to evaluate INF as a treatment modality under the rigor of scientific inquiry to determine its effectiveness as a viable treatment option for breast cancer patients with CIPN.
Interventions
- OTHER Arm 1: Investigational INF
- OTHER Arm 2: standardized muscle stretching and strength
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2017-09-28 |
| Est. Completion | 2022-05-25 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03272919
The ClinicalTrials.gov registry entry for NCT03272919 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loma Linda University, which has 237 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Arm 1: Investigational INF is the first listed.
NCT03272919 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03272919 about?
NCT03272919 is a clinical study titled "Chemotherapy Induced Peripheral Neuropathy (CIPN)". Chemotherapy induced peripheral neuropathy (CIPN) is a common side effect of many forms of chemotherapy having a negative impact on the quality of life for cancer survivors due to numbness, decreased sensation, pain (of various intensities in the extremities), gait/balance problems, and difficulty w...
What is the current status of trial NCT03272919?
This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2017-09-28. Estimated completion is 2022-05-25.
What interventions are being tested in trial NCT03272919?
The interventions under investigation include: Arm 1: Investigational INF (OTHER), Arm 2: standardized muscle stretching and strength (OTHER).
Who is sponsoring clinical trial NCT03272919?
This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.